Kyntra Bio Inc (KYNB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.55+0.71%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Grow revenue above $3.7M quarterly: rev -$1.5M vs $3.7M.
Kyntra Bio grew revenue from $1.3M to $3.7M in one quarter. The company aims to keep growing sales. Positive trial data supports future products. Management is working to reduce losses.
Kyntra Bio is still losing money with no clear profit path. Revenue growth may slow or stop. The company faces regulatory and financial risks.
The price is about 6% above our fair value near $7. Analysts expect 22% revenue growth. We see risks in loss reduction and profit timing.
Breaks if: trial data turns negative or fails to advance
Breaks if: operating losses worsen beyond -$13.8 million quarterly
Breaks if: quarterly revenue falls below $3.7 million
Grow total revenue from continuing operations compared to prior periods.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
KYNB represents a speculative growth investment. The company is currently loss-making and has a neutral management outlook, indicating uncertainty in its near-term trajectory.
The market appears to price KYNB as cheap compared to its peers, reflecting a significant expectations gap. This suggests that investors may have low expectations for near-term performance.
Fundamentals are likely to remain weak in the near term, especially given the recent earnings miss and elevated risk factors. However, management is making progress on key trials, which could provide some stability.
The long-term thesis hinges on the outcomes of ongoing clinical trials and the overall health of the healthcare sector. Any negative guidance or worsening economic indicators could further impact KYNB's performance.
In the next 1 to 3 years, KYNB's performance will depend on trial advancements and sector momentum, while facing risks from potential earnings guidance cuts. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read. However, the company reported a Q2 EPS miss, indicating ongoing operating losses. This raises concerns about its ability to reduce those losses moving forward.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.